EcoDrugPlus

C-X-C Motif Chemokine Receptor 2

Ensembl ID : ENSSAUG00010013662
Gene Symbol: CXCR2
1 Cross references
275 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSSAUG00010021600
Gene Symbol: CXCR4
3 Cross references
201 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSSAUG00010002074
Gene Symbol: LOC115567641
2 Cross references
408 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSSAUG00010013612
Gene Symbol: CFTR
3 Cross references
214 Possible Orthologues:

D(1)-Like Dopamine Receptor

Ensembl ID : ENSSAUG00010009352
Gene Symbol: LOC115594552
3 Cross references
199 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSSAUG00010025383
Gene Symbol: LOC115586103
3 Cross references
165 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSSAUG00010009735
Gene Symbol: DNMT1
3 Cross references
210 Possible Orthologues:

Dna Topoisomerase 1-Like

Ensembl ID : ENSSAUG00010013632
Gene Symbol: LOC115583648
3 Cross references
207 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSSAUG00010015283
Gene Symbol: TOP1
3 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSSAUG00010011221
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSSAUG00010014943
Gene Symbol: TOP2B
1 Cross references
207 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSSAUG00010019404
Gene Symbol: EPHA3
1 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).